Citi analyst Patrick Donnelly upgraded Thermo Fisher (TMO) to Buy from Neutral with a price target of $660, up from $580. The firm adjusted ratings in the life science tools and diagnostics group as part of its 2026 outlook. Citi sees Thermo Fisher benefitting from increased pharma spending and onshoring tailwinds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Synopsys upgraded, Warner Bros. downgraded: Wall Street’s top analyst calls
- Thermo Fisher initiated with a Buy at Goldman Sachs
- Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc
- Teva, Fastly, MP Materials, Lemonade, Thermo Fisher: Insider Sales Unveiled!
- Carvana, Zscaler, MPLX, EPD, Thermo Fisher Trending by Analysts